COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,019 Articles (22,627 medRxiv, 8,392 bioRxiv)

Most recent first Previous |  Page 2092: Articles 20911-20920  | Next

Structural Entropy of Daily Number of COVID-19 Related Fatalities
Unlu, E.
10.1101/2020.10.19.20215673 — Posted: 2020-10-31
Excess mortality during the COVID-19 pandemic in Aden governorate, Yemen: a geospatial and statistical analysis
Koum Besson, E. S., Norris, A., Bin Ghouth, A. S., Freemantle, T., Alhaffar, M., Vazquez, Y., Reeve, C., Curran, P. J., Checchi, F.
10.1101/2020.10.27.20216366 — Posted: 2020-10-31
From 5Vs to 6Cs: Operationalizing Epidemic Data Management with COVID-19 Surveillance
Peddireddy, A. S., Xie, D., Patil, P., Wilson, M. L., Machi, D., Venkatramanan, S., Klahn, B., Porebski, P., Bhattacharya, P., Dumbre, S., Marathe, M.
10.1101/2020.10.27.20220830 — Posted: 2020-10-31
Features of C-reactive protein in COVID-19 patients with different ages, clinical types and outcomes: a cohort study
Qu, G., Huang, G., Zhang, M., Yu, H., Song, X., Zhu, H., Chen, L., Wang, Y., Pei, B.
10.1101/2020.10.26.20220160 — Posted: 2020-10-31
Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses
Kistler, K., Bedford, T.
10.1101/2020.10.30.352914 — Posted: 2020-10-30
PRAK-03202: A triple antigen VLP vaccine candidate against SARS CoV-2
Mazumder, S., Rastogi, R., Undale, A., Arora, K., Arora, N. M., Das Purkayastha, B. P., Kumar, D., Joseph, A., Mali, B., Arya, V. B., Kalyanaraman, S., Mukherjee, A., Gupta, A., Potdar, S., Roy, S. S., Parashar, D., Paliwal, J., Singh, S. K., Naqvi, A., Srivastava, A., Singh, M. K., Kumar, D., Bansal, S., Rautray, S., Singh, I., Fengade, P., Kumar, B., Saini, M., Jain, K., Gupta, R., Kundu, P. K.
10.1101/2020.10.30.360115 — Posted: 2020-10-30
A cell-free antibody engineering platform rapidly generates SARS-CoV-2 neutralizing antibodies
Chen, X., Gentili, M., Hacohen, N., Regev, A.
10.1101/2020.10.29.361287 — Posted: 2020-10-30
COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning
The COVID Moonshot Consortium, , Achdout, H., Aimon, A., Bar-David, E., Barr, H., Ben-Shmuel, A., Bennett, J., Bobby, M. L., Brun, J., BVNBS, S., Calmiano, M., Carbery, A., Cattermole, E., Chodera, J. D., Clyde, A., Coffland, J. E., Cohen, G., Cole, J., Contini, A., Cox, L., Cvitkovic, M., Dias, A., Douangamath, A., Duberstein, S., Dudgeon, T., Dunnett, L., Eastman, P. K., Erez, N., Fairhead, M., Fearon, D., Fedorov, O., Ferla, M., Foster, H., Foster, R., Gabizon, R., Gehrtz, P., Gileadi, C., Giroud, C., Glass, W. G., Glen, R., Glinert, I., Gorichko, M., Gorrie-Stone, T., Griffen, E. J., Heer, J., Hill, M., Horrell, S., Hurley, M. F. D., Israely, T., Jajack, A., Jnoff, E., John, T., Kantsadi, A. L., Kenny, P. W., Kiappes, J. L., Koekemoer, L., Kovar, B., Krojer, T., Lee, A. A., Lefker, B. A., Levy, H., London, N., Lukacik, P., Macdonald, H. B., MacLean, B., Malla, T. R., Matviiuk, T., McCorkindale, W., Melamed, S., Michurin, O., Mikolajek, H., Morris, A., Morris, G. M., Morwitzer, M. J., Moustakas, D., Neto, J. B., Oleinikovas, V., Overheul, G. J., Owen, D., Pai, R., Pan, J., Paran, N., Perry, B., Pingle, M., Pinjari, J., Politi, B., Powell, A., Psenak, V., Puni, R., Rangel, V. L., Reddi, R. N., Reid, S. P., Resnick, E., Robinson, M. C., Robinson, R. P., Rufa, D., Schofield, C., Shaikh, A., Shi, J., Shurrush, K., Sittner, A., Skyner, R., Smalley, A., Smilova, M. D., Spencer, J., Strain-Damerell, C., Swamy, V., Tamir, H., Tennant, R., Thompson, A., Thompson, W., Tomasio, S., Tumber, A., Vakonakis, I., van Rij, R. P., Varghese, F. S., Vaschetto, M., Vitner, E. B., Voelz, V., von Delft, A., von Delft, F., Walsh, M., Ward, W., Weatherall, C., Weiss, S., Wild, C. F., Wittmann, M., Wright, N., Yahalom-Ronen, Y., Zaidmann, D., Zidane, H., Zitzmann, N.
10.1101/2020.10.29.339317 — Posted: 2020-10-30
Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes
Andring, J. T., McKenna, R., Stevens, B. R.
10.1101/2020.10.30.361873 — Posted: 2020-10-30
Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2
Bakovic, A., Risner, K., Bhalla, N., Alem, F., Chang, T. L., Weston, W., Harness, J. A., Narayanan, A.
10.1101/2020.10.29.352450 — Posted: 2020-10-30 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).